Devic’s neuromyelitis optica (NMO) is a rare inflammatory disease of the
central nervous system that results in optic neuropathy and myelitis.Optic
neuritis represents the mode of entry into the disease in more than two thirds of cases. It isa rare entity in children.There is no effective treatment at present, but some molecules can be used, such as corticosteroids,
immunosuppressants and plasma exchange. The prognosis in children is generally
favorable. Devic’s neuromyelitis is a
condition of unknown etiopathogeny which is functionally critical and
requires early and appropriate treatment. We report the case of a 12-year-old
girl who presented to emergency with a headache and decreased visual acuity,
whose investigations led to the diagnosis of Devic’s neuromyelitis optica.
References
[1]
Goetz, C.G. (1999) Demyelinating Disorders of the Central Nervous System (Chapter 48). In: Hogancamp, W.E. and Noseworthy, J.H., Eds., Textbook of Clinical Neurology, 970-986.
[2]
Jouhadi, Z., Ouazzani, I., Abid, A., El Moutawakil, B., Rafai, M.A. and Slassi, I. (2004) Neuromyelitis optica de Devic and viral hepatitis AA propos d’une observation pédiatrique. Revue Neurologique, 160, 1198-1120.
https://doi.org/10.1016/S0035-3787(04)71167-4
[3]
Wingerchuk, D.M., Lennon, V.A., Pittock, S.J., Luccinetti, C.F. and Weinshenker, B.G. (2006) Revised Diagnosis for Neuromyelitisoptica. American Journal of Ophthalmology, 142, 715-716. https://doi.org/10.1016/j.ajo.2006.08.010
[4]
Lafitte, C. (2002) Neurological Manifestations of Primary Sjögren’s Syndrome. Revue Neurologique, 10, 959-965.
[5]
De Seze, J., Stojkovic, T. and Hachulla, E. (2001) Myelopathies and Gougerot-Sjögren Syndrome: Clinical, Radiological and Evolutionary Profile. Revue Neurologique, 157, 669-678.
[6]
Gökcay, F., Celebisoy, N., Gökcay, A., Kabasakal, Y. and Oder, G. (2007) Primary Sjogren’s Syndrome Presenting as Neuromyelitis Optica. Pediatric Neurology, 36, 58-60. https://doi.org/10.1016/j.pediatrneurol.2006.07.008
[7]
De Seze, J., Stojkovic, T., Ferriby, D., Gauvrit, J.Y., Montagne, C. and Mounier-Vehier, F. (2002) Devic’s Neuromyelitis Optica: Clinical, Laboratory, MRI and Outcome Profile. Journal of Neuroscience, 197, 57-61.
https://doi.org/10.1016/S0022-510X(02)00043-6
[8]
Mochizuki, A., Hayashi, A., Hisahara, S. and Shoji, S. (2000) Steroid-Responsive Devic’s Variantin Sjögren’s Syndrome. Neurology, 54, 1391-1392.
https://doi.org/10.1212/WNL.54.6.1391
[9]
Mandler, R., Ahmed, W. and Dencoff, J. (1998) Devic’s Neuromyelitis Optica: A Prospective Study of Seven Patients Treated with Prednisone and Azathioprine. Neurology, 51, 1219-1220. https://doi.org/10.1212/WNL.51.4.1219
[10]
Cree, B., Lamb, S., Morgan, K., Chen, A., Waubant, E. and Genain, C. (2005) An Open Label Study of the Effects of Rituximab in Neuromyelitisoptica. Neurology, 64, 1270-1272. https://doi.org/10.1212/01.WNL.0000159399.81861.D5
[11]
Williams, C.S., Butler, E. and Roman, G.C. (2001) Treatment of Myelopathy in Sjögren’s Syndrome with a Combination of Prednisone and Cyclophosphamide. Archives of Neurology, 58, 815-819. https://doi.org/10.1001/archneur.58.5.815
